Neuronal Intranuclear and Neuropil Inclusions for Pathological Assessment of Huntington's Disease

Overview

Journal Brain Pathol

Date 2007 May 12

PMID 17493035

Citations 10

Authors

Marion Maat-Schieman

Raymund Roos

Monique Losekoot

Josephine Dorsman

Corrie Welling-Graafland

Ingrid Hegeman-Kleinn

Freerk Broeyer

Martijn Breuning

Sjoerd van Duinen

Affiliations

Soon will be listed here.

Abstract

To evaluate the usefulness of neuronal intranuclear inclusions and neuropil inclusions for the pathological assessment of Huntington's disease (HD), their presence in neocortex was assessed by ubiquitin and N-terminal huntingtin immunohistochemistry in a consecutive series of 195 autopsy brains of individuals with a positive or tentative clinical diagnosis of, or at risk for, HD. The findings were correlated with striatal pathology (n = 190), CAG repeat length (n = 85) and original pathological diagnosis (n = 186). The antibodies detected both these inclusions in 181 patients with HD pathology > or = Vonsattel et al's grade I, five patients lacking striatal tissue for review, and two at-risk individuals with grade 0 and grade I HD pathology, respectively. One patient with HD-like pathology and two patients and four at-risk individuals without HD pathology lacked HD inclusions. In the genetically analyzed cases, the inclusions were exclusively and consistently observed in association with repeat expansion [(CAG)(n) > or = 39, n = 81]. Thirteen inclusion-positive cases, including the grade 0 at-risk individual, had a false negative original pathological diagnosis of HD and four had an unjustly questionable diagnosis. A false positive diagnosis was made in the inclusion-negative case with HD-like pathology. These results indicate that immunohistochemical analysis for HD inclusions facilitates the pathological evaluation of HD and enhances its accuracy.

Citing Articles

Postmortem neuropathology in early Huntington disease.

Hedreen J, Berretta S, White Iii C J Neuropathol Exp Neurol. 2024; 83(5):294-306.

PMID: 38553027 PMC: 11029463. DOI: 10.1093/jnen/nlae022.

Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.

Rub U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K Brain Pathol. 2014; 24(3):247-60.

PMID: 24779419 PMC: 4160739. DOI: 10.1111/bpa.12115.

Deciphering the roles of trehalose and Hsp104 in the inhibition of aggregation of mutant huntingtin in a yeast model of Huntington's disease.

Chaudhary R, Kardani J, Singh K, Banerjee R, Roy I Neuromolecular Med. 2013; 16(2):280-91.

PMID: 24248470 DOI: 10.1007/s12017-013-8275-5.

Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.

Xu Q, Huang S, Song M, Wang C, Yan S, Liu X J Cell Biol. 2013; 202(7):1123-38.

PMID: 24081492 PMC: 3787372. DOI: 10.1083/jcb.201303146.

EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease.

Losekoot M, van Belzen M, Seneca S, Bauer P, Stenhouse S, Barton D Eur J Hum Genet. 2012; 21(5):480-6.

PMID: 22990145 PMC: 3641377. DOI: 10.1038/ejhg.2012.200.

References

Sieradzan K, Mechan A, Jones L, Wanker E, Nukina N, Mann D . Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol. 1999; 156(1):92-9. DOI: 10.1006/exnr.1998.7005. View

. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997; 18(4 Suppl):S1-2. View

Dickson T, King C, McCormack G, Vickers J . Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp Neurol. 1999; 156(1):100-10. DOI: 10.1006/exnr.1998.7010. View

Kambouris M, Bohlega S, Al-Tahan A, Meyer B . Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet. 2000; 66(2):445-52. PMC: 1288097. DOI: 10.1086/302744. View

Kakita A, Oyanagi K, Nagai H, Takahashi H . Eosinophilic intranuclear inclusions in the hippocampal pyramidal neurons of a patient with amyotrophic lateral sclerosis. Acta Neuropathol. 1997; 93(5):532-6. DOI: 10.1007/s004010050649. View

Davies S, Turmaine M, Cozens B, DiFiglia M, Sharp A, Ross C . Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997; 90(3):537-48. DOI: 10.1016/s0092-8674(00)80513-9. View

Stevenson V, Hardie R . Acanthocytosis and neurological disorders. J Neurol. 2001; 248(2):87-94. DOI: 10.1007/s004150170241. View

Vonsattel J, Myers R, Stevens T, Ferrante R, BIRD E, Richardson Jr E . Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985; 44(6):559-77. DOI: 10.1097/00005072-198511000-00003. View

Jackson M, Gentleman S, Lennox G, Ward L, Gray T, Randall K . The cortical neuritic pathology of Huntington's disease. Neuropathol Appl Neurobiol. 1995; 21(1):18-26. DOI: 10.1111/j.1365-2990.1995.tb01024.x. View

10.

. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993; 72(6):971-83. DOI: 10.1016/0092-8674(93)90585-e. View

11.

Litvan I, Hauw J, Bartko J, Lantos P, Daniel S, Horoupian D . Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996; 55(1):97-105. DOI: 10.1097/00005072-199601000-00010. View

12.

Charles V, Mezey E, Reddy P, Dehejia A, Young T, Polymeropoulos M . Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci Lett. 2000; 289(1):29-32. DOI: 10.1016/s0304-3940(00)01247-7. View

13.

Schilling G, Becher M, Sharp A, Jinnah H, Duan K, Kotzuk J . Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999; 8(3):397-407. DOI: 10.1093/hmg/8.3.397. View

14.

Stevanin G, Fujigasaki H, Lebre A, Camuzat A, Jeannequin C, Dode C . Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain. 2003; 126(Pt 7):1599-603. DOI: 10.1093/brain/awg155. View

15.

Everett C, Wood N . Trinucleotide repeats and neurodegenerative disease. Brain. 2004; 127(Pt 11):2385-405. DOI: 10.1093/brain/awh278. View

16.

Moore R, Xiang F, Monaghan J, Han D, Zhang Z, Edstrom L . Huntington disease phenocopy is a familial prion disease. Am J Hum Genet. 2001; 69(6):1385-8. PMC: 1235549. DOI: 10.1086/324414. View

17.

Caramins M, Halliday G, McCusker E, Trent R . Genetically confirmed clinical Huntington's disease with no observable cell loss. J Neurol Neurosurg Psychiatry. 2003; 74(7):968-70. PMC: 1738566. DOI: 10.1136/jnnp.74.7.968. View

18.

Seilhean D, Takahashi J, El Hachimi K, Fujigasaki H, Lebre A, Biancalana V . Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions. Acta Neuropathol. 2004; 108(1):81-7. DOI: 10.1007/s00401-004-0855-x. View

19.

Bauer P, Laccone F, Rolfs A, Wullner U, Bosch S, Peters H . Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J Med Genet. 2004; 41(3):230-2. PMC: 1735701. DOI: 10.1136/jmg.2003.015602. View

20.

Sapp E, Penney J, Young A, Aronin N, Vonsattel J, DiFiglia M . Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol. 1999; 58(2):165-73. DOI: 10.1097/00005072-199902000-00006. View